Citius Pharmaceuticals, Inc. (CTXR) - 10-K Summary
Business Context and Reporting Period
Company: Citius Pharmaceuticals, Inc. (Nasdaq: CTXR)
Reporting Period: Fiscal Year Ended September 30, 2025
Business Overview: Citius is a biopharmaceutical company focused on critical care products, oncology, and anti-infectives. The company operates through its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), which holds the rights to the company's only approved product, LYMPHIR (denileukin diftitox), for the treatment of cutaneous T-cell lymphoma (CTCL). LYMPHIR was FDA-approved in August 2024 and commercially launched in December 2025. Other pipeline assets include Mino-Lok (catheter salvage solution, Phase 3 complete), Halo-Lido (hemorrhoid treatment, Phase 2 complete), and NoveCite (stem cell therapy for ARDS, development paused).
Key Financial Metrics
| Metric | Fiscal Year 2025 | Fiscal Year 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(39,740,269) | $(39,425,839) |
| Operating Expenses | $38,525,608 | $41,995,681 |
| Cash and Cash Equivalents (Sept 30, 2025) | $4,252,290 | $3,251,880 |
| Working Capital | $(16,980,000) | Not Disclosed |
| Accumulated Deficit | $(238,804,129) | $(201,370,218) |
| Inventory (Finished Goods & WIP) | $22,286,693 | $8,268,766 |
Note: Revenue commenced in December 2025, subsequent to the fiscal year-end.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately $3.5 million (8.3%) year-over-year, driven primarily by a $2.75 million reduction in Research and Development (R&D) costs following the completion of the Mino-Lok Phase 3 trial and reduced Halo-Lido development activities.
- Inventory Build-up: Inventory increased significantly by $14.0 million to $22.3 million, reflecting the accumulation of finished goods and work-in-process for LYMPHIR in preparation for the December 2025 commercial launch.
- Other Income: The company recognized a $2.4 million gain in 2024 from the sale of New Jersey net operating losses, which was not present in 2025.
- Interest Expense: Interest expense of $267,782 was recorded in 2025, primarily due to interest on a payment agreement with Eisai and a new note payable, compared to zero in 2024.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: The independent auditor has issued an explanatory paragraph stating there is substantial doubt about the company's ability to continue as a going concern. Management estimates current cash resources, combined with $6.0 million raised in October 2025 and $18.0 million raised by Citius Oncology in December 2025, will fund operations only through March 2026.
Outlook and Strategy:
- LYMPHIR Commercialization: The company is heavily dependent on the commercial success of LYMPHIR. Distribution agreements are in place with Cardinal Health, Cencora, and McKesson. The product was included in NCCN guidelines in September 2024.
- Mino-Lok: Phase 3 trial results were positive (May 2024). The company is engaging with the FDA to define the regulatory path for a New Drug Application (NDA).
- Strategic Alternatives: Management is evaluating strategic alternatives, including partnerships, mergers, or acquisitions, to secure necessary capital. If these fail, the Board may consider dissolution and liquidation.
Key Risks and Contingencies:
- Licensing Obligations: As of September 30, 2025, the company had outstanding milestone payments of approximately $22.65 million (License Payable) to Eisai and Dr. Reddy's. Failure to make timely payments could result in license termination.
- Manufacturing Commitments: The company has minimum purchase commitments of approximately $21.1 million for drug substance and finished product manufacturing through 2027.
- Capital Needs: Substantial additional funding is required beyond March 2026 to satisfy milestone obligations and fund operations. There is no assurance that financing will be available on acceptable terms.
- Ownership Structure: Citius Pharma owns approximately 77.9% of Citius Oncology. A planned distribution of Citius Oncology shares to stockholders may result in significant tax liability and reduce Citius Pharma's future benefit from LYMPHIR commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $24 million raised in October and December 2025 to cover the $22.65 million in immediate licensing liabilities and operating burn through March 2026.
- LYMPHIR Sales Data: Monitor initial sales figures and reimbursement rates following the December 2025 launch to assess revenue generation potential.
- Milestone Payment Schedule: Confirm adherence to the payment schedule with Eisai (final payment due December 15, 2025) and Dr. Reddy's to avoid license termination.
- Strategic Transaction Progress: Track any announcements regarding partnerships, mergers, or additional equity raises required to extend the operating runway beyond March 2026.
- NoveCite Status: Note that development of the NoveCite stem cell therapy has been paused to prioritize LYMPHIR and Mino-Lok.